MedPath

Cisplatin

Generic Name
Cisplatin
Brand Names
Platinol
Drug Type
Small Molecule
Chemical Formula
Cl2H6N2Pt
CAS Number
15663-27-1
Unique Ingredient Identifier
Q20Q21Q62J
Background

Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin.

Indication

For the treatment of metastatic testicular tumors, metastatic ovarian tumors and advanced bladder cancer.

Associated Conditions
Advanced Ovarian Cancer, Ovarian Cancer Metastatic, Advanced Bladder cancer, Advanced Testicular cancer, Metastatic Testicular cancer
Clinical Trials
Related News

Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC)

Phase 1
Not yet recruiting
Conditions
Non-small Cell Lung Cancer (NSCLC)
Carcinoma, Non-Small Cell Lung
Non-Small Cell Lung Carcinoma
Non Small Cell Lung Cancer
Non Small Cell Lung Carcinoma
Interventions
First Posted Date
2024-11-19
Last Posted Date
2025-05-22
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
60
Registration Number
NCT06694454
Locations
🇺🇸

National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Study of Precision Treatment for Rare Tumours in China Guided by PDO and NGS

First Posted Date
2024-11-18
Last Posted Date
2024-11-18
Lead Sponsor
Peking University Shenzhen Hospital
Target Recruit Count
200
Registration Number
NCT06692491

A Study to Compare Pharmacokinetics, Efficacy, Safety, and Immunogenicity of MB12 (Proposed Pembrolizumab Biosimilar) to Keytruda® in Non-small Cell Lung Cancer (BENITO Study)

Phase 3
Recruiting
Conditions
Non Squamous Non Small Cell Lung Cancer
Interventions
Drug: EU-sourced Keytruda®
Drug: US-sourced Keytruda®
First Posted Date
2024-11-13
Last Posted Date
2025-05-21
Lead Sponsor
mAbxience Research S.L.
Target Recruit Count
726
Registration Number
NCT06687369
Locations
🇬🇪

Site 108002, Tbilisi, Georgia

🇷🇸

Site 121005, Užice, Serbia

🇯🇵

Site 207002, Hakodate-shi, Japan

and more 13 locations

Safety and Efficacy of SYHA1813 Single Agent or in Combination With Different Regimens in Unresectable Locally Advanced or Metastatic Solid Tumors.

Phase 1
Not yet recruiting
Conditions
Unresectable Locally Advanced or Metastatic Solid Tumors
Interventions
First Posted Date
2024-11-11
Last Posted Date
2024-11-11
Lead Sponsor
Shanghai Runshi Pharmaceutical Technology Co., Ltd
Target Recruit Count
380
Registration Number
NCT06682611

Perioperative Tislelizumab for Resectable II-IIIB(N2) KRAS-mutated Nonsquamous Non-small Cell Lung Cancer

Phase 2
Recruiting
Conditions
Lung Cancer, Non-Small Cell
Interventions
First Posted Date
2024-10-26
Last Posted Date
2025-05-18
Lead Sponsor
Shanghai Chest Hospital
Target Recruit Count
32
Registration Number
NCT06659042
Locations
🇨🇳

Shanghai Chest Hospital, Shanghai, Shanghai, China

Neoadjuvant Toripalimab + Chemotherapy ± Cetuximab in Locally Advanced Head and Neck Squamous Cell Carcinoma (Neo-ICT)

Phase 3
Not yet recruiting
Conditions
Squamous Cell Carcinoma of Head and Neck
Interventions
Radiation: Radiotherapy 60 Gray/day
Radiation: Radiotherapy 66 Gray/day
Radiation: Radiotherapy 70 Gray/day
First Posted Date
2024-10-18
Last Posted Date
2024-10-18
Lead Sponsor
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
Target Recruit Count
355
Registration Number
NCT06647563

Comparing Impact of Treatment Before or After Surgery in Patients With Stage II-IIIB Resectable Non-small Cell Lung Cancer

Phase 3
Recruiting
Conditions
Resectable Lung Non-Small Cell Carcinoma
Stage II Lung Cancer AJCC v8
Stage IIIA Lung Cancer AJCC v8
Stage IIIB Lung Cancer AJCC v8
Interventions
Procedure: Surgical Procedure
Procedure: Computed Tomography
Procedure: Magnetic Resonance Imaging
Procedure: Positron Emission Tomography
First Posted Date
2024-10-09
Last Posted Date
2025-03-30
Lead Sponsor
Alliance for Clinical Trials in Oncology
Target Recruit Count
1100
Registration Number
NCT06632327
Locations
🇺🇸

South Sacramento Cancer Center, Sacramento, California, United States

🇺🇸

Kaiser Permanente-San Francisco, San Francisco, California, United States

🇺🇸

Kaiser Permanente-Santa Teresa-San Jose, San Jose, California, United States

and more 223 locations

Hepatic Arterial Infusion Chemotherapy With Lipiodol Embolization in Advanced Hepatocellular Carcinoma

Phase 2
Recruiting
Conditions
Hepatocellular Carcinoma
Interventions
Procedure: Lipiodol embolization
First Posted Date
2024-10-09
Last Posted Date
2024-10-09
Lead Sponsor
National Taiwan University Hospital
Target Recruit Count
24
Registration Number
NCT06632717
Locations
🇨🇳

National Taiwan University Hospital, Taipei, Taiwan

A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Non-squamous NSCLC

Phase 3
Recruiting
Conditions
Non-squamous Non-small Cell Lung Cancer
Interventions
First Posted Date
2024-10-04
Last Posted Date
2025-05-07
Lead Sponsor
AstraZeneca
Target Recruit Count
878
Registration Number
NCT06627647
Locations
🇻🇳

Research Site, Vinh, Vietnam

A Study to See How Well and How Safely Different Treatments Work in a Group of Participants With Non-Small Cell Lung Cancer (NSCLC)

Phase 3
Recruiting
Conditions
Non-Small Cell Lung Cancer
Interventions
First Posted Date
2024-10-02
Last Posted Date
2025-04-27
Lead Sponsor
Hoffmann-La Roche
Target Recruit Count
150
Registration Number
NCT06624059
Locations
🇦🇺

Royal North Shore Hospital, St. Leonards, New South Wales, Australia

🇦🇺

Calvary Mater Newcastle, Waratah, New South Wales, Australia

🇨🇳

Xiangya Hospital of Centre-South University, Changsha, China

and more 14 locations
© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy